Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive sarcoma. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) may improve survival. A retrospective review of anesthetic management and postoperative pain control strategies after CRS/HIPEC for DSRCT from 2013 to 2017 was performed. The review analyzed 10 CRS/HIPEC procedures performed for nine DSRCT patients with a median age of 19years (range 10-24years). Six of these patients were Caucasian, and seven were men. The median operative duration was 551min (range 510-725min), and the median anesthesia duration was 621min (range 480-820min). Postoperative mechanical ventilation was necessary in 5 patients for a median duration of 1day (range 0-2days). The median intraoperative intravenous fluid administration was 13ml/kg/h (range 6.3-24.4ml/kg/h), and the colloid administration was 12ml/kg (range 0.0-53.0ml/kg). The median blood loss was 15ml/kg (range 6.3-77.2ml/kg). Nine patients received intraoperative transfusion with a median red blood cell transfusion volume of 14ml/kg (range 10.1-58.5ml/kg). The median intraoperative urine output was 2ml/kg/h (range 0.09-8.40ml/kg/h), and half of the patients received intraoperative diuretics. Cisplatin was used during HIPEC for eight surgeries. Acute kidney injury was observed in two patients, one of whom required short-term dialysis. Epidural infusions were used in eight cases for a median of 4days (range 3-5days). Postoperative intravenous opioid use (morphine equivalent) was 0.67mg/kg/day (range 0.1-9.2mg/kg/day) administered for a median of 11days (range 2-35days). Cytoreduction and HIPEC for DSRCT are associated with significant perioperative fluid requirements and potentially challenging pain management. Renal protective strategies should be considered for reduction of cisplatin-associated nephrotoxicity. Further investigation for a more effective, less systemically toxic HIPEC agent is warranted.